Ads by Google

Drug Clinical Trials

Akela Pharma Announces Positive Results From Growth Hormone Releasing Hormone Trial

Akela Pharma announced positive final results from its pilot GHRH Phase II study. Within only 4 weeks of treatment, Akela GHRH induced a highly significant stimulation of endogenous growth hormone (GH) secretion and a marked increase of circulating insulin-like growth factor(IGF-1) as compared to placebo in patients with chronic kidney disease.

Health and Wellness: 

Trial Of XL784 In Patients With Proteinuria Associated With Diabetic Nephropathy Shows Negative Results

Exelixis recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. Exelixis is continuing to analyze the data to assess whether further evaluation of the compound is warranted.

Health and Wellness: 

Three Clinical Trials For Perforomist Inhalation Solution Are Promising

Dey L.P. will present data from two safety studies that were included as part of the New Drug Application (NDA) filing to FDA for Perforomist Inhalation Solution. The third presents results from a Phase IIIb study of the concomitant use of Perforomist Inhalation Solution with tiotropium for the treatment of COPD.

Health and Wellness: 

PTC Therapeutics Announces Encouraging Phase 2 Results Of PTC124 In Cystic Fibrosis

PTC Therapeutics announced encouraging data from a Phase 2 clinical trial of PTC124 in pediatric patients with cystic fibrosis (CF) due to a nonsense mutation. These pediatric results and additional information emerging from long-term studies support the existing data from prior short- term studies in adult CF patients. These studies show that treatment with PTC124 results in statistically significant improvements in a measure of the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Health and Wellness: 

Pages